Information from the abstract
BACKGROUND: Eosinophils are involved in the pathogenesis of atopic dermatitis (AD). OBJECTIVE: This post-hoc analysis evaluated the effect of stapokibart on blood eosinophil counts in moderate-to-severe AD patients. METHODS: = 500) randomly assigned patients to stapokibart 300 mg Q2W or placebo for 16 weeks, followed by open-label stapokibart 300 mg Q2W for 36 weeks. Efficacy and safety were analyzed in subgroups stratified by baseline blood eosinophil counts (≥500 or
Why this record is monitored
This record has an Impact Signal of 72/100 based on recency, source, collaboration, and bibliographic signals. It prioritizes monitoring and is not a judgment of research quality.
Related topics: Dermatology and Skin Diseases · Asthma and respiratory diseases · Eosinophilic Disorders and Syndromes
Thai researcher and institutional participation
Qianjin Lu · Institute of Dermatology
Data limitations
This page is a bibliographic record based on abstract-level information, not a full analysis or quality assessment. Verify the DOI and original article before citation.